To test whether the establishment of a CD200 TME that specifically targets NK cells was essential for BCC growth, we pretreated nude mice with an NK cell–depleting antibody before grafting primary human BCC and SCC cells. The gene discussed is CD200; the disease is skin basal cell carcinoma.